Carri, I., Schwab, E., Trivino, J. C., Von Euw, E. M., Nielsen, M., Mordoh, J., & Barrios, M. M. (2025). VACCIMEL, an allogeneic melanoma vaccine, efficiently triggers T cell immune responses against neoantigens and alloantigens, as well as against tumor-associated antigens. Web
Citación estilo ChicagoCarri, Ibel, Erika Schwab, Juan Carlos Trivino, Erika María Von Euw, Morten Nielsen, José Mordoh, and María Marcela Barrios. VACCIMEL, an Allogeneic Melanoma Vaccine, Efficiently Triggers T Cell Immune Responses against Neoantigens and Alloantigens, As Well As against Tumor-associated Antigens. 2025.
Cita MLACarri, Ibel, et al. VACCIMEL, an Allogeneic Melanoma Vaccine, Efficiently Triggers T Cell Immune Responses against Neoantigens and Alloantigens, As Well As against Tumor-associated Antigens. 2025.